financetom
Business
financetom
/
Business
/
5G testing not behind spike in COVID cases, rumour mongers to face action: Haryana govt
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
5G testing not behind spike in COVID cases, rumour mongers to face action: Haryana govt
May 21, 2021 4:03 AM

Days after the fact-checking team of the Press Information Bureau (PIB) busted a conspiracy theory stating that 5G testing is the reason behind the sudden surge in COVID-19 cases in India, the Haryana government on May 20 directed top police officials to take action against people who are spreading such rumours.

The official order, issued by Haryana Chief Secretary Vijai Vardhan said, “As you might be aware, misinformation attributing the fatalities and health problems being faced by people due to the COVID-19 virus, is being attributed to testing of 5G towers. This has led to some incidents in the state resulting in mobile towers/networks being damaged by some misguided elements.”

The order also cited the clarification issued by the World Health Organisation (WHO) stating that viruses cannot travel on radio waves or mobile networks. “The Department of Telecommunication has clarified that linking the 5G network technology with COVID-19 pandemic has no scientific basis. Besides, the testing of the 5G network has not yet started in India. Hence, the apprehension that 5G trials/networks causing COVID in India is baseless and devoid of any merit,” added the order.

Earlier this month, an audio message was intercepted by the PIB in which a man was heard saying that people are dying in states like Uttar Pradesh, Maharashtra, and Bihar because of 5G testing. Through a tweet, PIB clarified, “In an audio message, it is being claimed that 5g network is being tested in the states, due to which people are dying. This claim is fake. Please do not spread confusion by sharing such fake messages.”

The Cellular Operators Association of India has also urged people to not believe in such rumours.

Similar rumours also gained steam in the United Kingdom last year, following which, a few 5G towers were dismantled there.

On May 11, the central government allowed Bharti Airtel, Reliance Jio Infocomm, Vi (Vodafone-Idea) and Mahanagar Telephone Nigam Limited (MTNL) to start trials for 5G technology. The trials are to go on for six months.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Nov 13, 2025
Overview * Arbutus Q3 revenue and net income missed analyst expectations * Company reports 46% of Phase 2a patients discontinued treatment in imdusiran trials * Arbutus continues litigation against Moderna and Pfizer/BioNTech over LNP technology Outlook * Favorable claim construction ruling in Pfizer-BioNTech litigation, Moderna trial set for March 2026 * 46% of Phase 2a patients discontinued treatment, showing potential...
Sagimet Biosciences Q3 net loss narrows as costs drop
Sagimet Biosciences Q3 net loss narrows as costs drop
Nov 13, 2025
Overview * Sagimet reports Q3 net loss of $12.9 mln * R&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024 * Cash and equivalents stand at $125.5 mln as of September 30, 2025 Outlook * Sagimet anticipates Phase 1 trial data readout for denifanstat and resmetirom in 1H 2026 * Company plans Phase 2...
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Aldeyra Therapeutics Expands RASP Platform to Include Central Nervous System Diseases
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Aldeyra Therapeutics ( ALDX ) said Thursday it is expanding its RASP platform to include programs targeting central nervous system diseases associated with inflammation. The company said new preclinical results in models of Parkinson's disease and amyotrophic lateral sclerosis showed improved grip strength, balance, and biomarkers of central nervous system function. The results...
Top Premarket Gainers
Top Premarket Gainers
Nov 13, 2025
07:41 AM EST, 11/13/2025 (MT Newswires) -- Mersana Therapeutics ( MRSN ) stock was up more than three-fold pre-bell Thursday after the company agreed to be acquired by Day One Biopharmaceuticals (DAWN) in a deal worth $285 million. Sealed Air ( SEE ) shares were 21% higher after The Wall Street Journal reported late Wednesday that the company is in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved